BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  << Back  |   Print
 
Torii, Toray Start to Co-Promote Hemoperfusion Absorption Column Toraymyxin for Removing Endotoxin

Tokyo, June 29, 2007 - (JCN Newswire) - Torii Pharmaceutical Co., Ltd. and Toray Industries, Inc. announced that the companies would start joint promotion of Toraymyxin (PMX-20R, PMX-05R) from July 2, 2007 in Japan, a hemoperfusion absorption column for removing endotoxin, which was developed by Toray. Currently, Toray manufactures Toraymyxin which has been marketed by Toray Medical Co., Ltd., a wholly owned subsidiary of Toray.

Toraymyxin, a blood purification device (column), absorbs the bacterial toxin (endotoxin) that causes sepsis and septic shock using a special fiber. It consists of a plastic cylindrical container filled with a special fiber composite immobilized with the antibiotic polymyxin B, which has high affinity for endotoxin. Toray in 1993 received approval for manufacturing and marketing of the product from then the "Health and Welfare Ministry of Japan," and Toray Medical has been marketing it since 1994. Toraymyxin is designed to selectively absorb and remove endotoxin in the bloodstream, which is believed to be responsible for sepsis.

Torii, Toray and Toray Medical believe that the tie-up would enable provision of superior products and information faster and in a more detailed manner to medical experts who engage in urgent medical treatment and intensive care, leading to further contribution to improvements of patients as well as advancement of medical technology.

About Torii Pharmaceutical Co., Ltd.

Torii Pharmaceutical Co., Ltd., established in 1921, has manufactured and distributed ethical pharmaceutical products. In 1998, Torii became a member of the JT Group. To maximally leverage the synergy of the Group, R&D functions were transferred to JT and sales and marketing functions were transferred to Torii. Torii and JT continue to operate in close collaboration.

About Toray

Toray, a leading diversified chemicals corporate group, has been technology-focused since its foundation in 1926. The company's operations are underpinned by technological expertise in organic synthetic chemistry, polymer chemistry, and biochemistry - Toray's three core technologies. These innovative technologies have yielded "advanced materials" that Toray is now exploiting to provide customers with comprehensive solutions through Fibers and Textiles, Plastics and Chemicals, IT-related Products, Housing and Engineering, Pharmaceuticals and Medical Products, New Products and Other Business divisions. In FY2006, Toray had consolidated sales of 1,547 billion yen, and over 34,670 employees worldwide.


Contact:

Toray Industries Corporate Communications Dept. Tel: +81-3-3245-5179
 
June 29, 2007
Source: Torii Pharmaceutical Co., Ltd.
Source: Toray

Torii Pharmaceutical Co., Ltd. (TSE: 4551)
Toray (TSE: 3402) (U.S: TRYIY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary